Keloids - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Keloids - Pipeline Review, H1 2018’, provides an overview of the Keloids pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Keloids, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Keloids and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Keloids

- The report reviews pipeline therapeutics for Keloids by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Keloids therapeutics and enlists all their major and minor projects

- The report assesses Keloids therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Keloids

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Keloids

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Keloids pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

FirstString Research Inc

RXi Pharmaceuticals Corp

Topadur Pharma AG

Tumorend LLC

Yuhan Corp

FirstString Research Inc

RXi Pharmaceuticals Corp

Topadur Pharma AG

Tumorend LLC

Yuhan Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Keloids – Overview

Keloids – Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Keloids – Overview

Keloids – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Keloids – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Keloids – Companies Involved in Therapeutics Development

FirstString Research Inc

RXi Pharmaceuticals Corp

Topadur Pharma AG

Tumorend LLC

Yuhan Corp

Keloids – Drug Profiles

CM-101 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Granexin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

koebnerisin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

psoriasin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RXI-109 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOPN-44 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YHC-1113 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Keloids – Dormant Projects

Keloids – Discontinued Products

Keloids – Product Development Milestones

Featured News & Press Releases

Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology

Apr 29, 2014: RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study

Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders

Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period

Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision

Jun 06, 2013: RXi Pharmaceuticals Announces Positive Results In First Double Blind Study In Healthy Volunteers With RXI-109

Jan 30, 2013: RXi Pharma Completes Enrollment In Second Phase I Trial For RXI-109 Program

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Keloids, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under ...

List of Tables

Number of Products under Development for Keloids, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Keloids – Pipeline by FirstString Research Inc, H1 2018

Keloids – Pipeline by RXi Pharmaceuticals Corp, H1 2018

Keloids – Pipeline by Topadur Pharma AG, H1 2018

Keloids – Pipeline by Tumorend LLC, H1 2018

Keloids – Pipeline by Yuhan Corp, H1 2018

Keloids – Dormant Projects, H1 2018

Keloids – Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Keloids, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by ...

List of Figures

Number of Products under Development for Keloids, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports